Oncology Market Access at Risk: Is a Carrot for MDs a Stick for Pharma Companies?

Howard Deutsch

( /-/media/files/publications/public/oncology-market-access-at-risk-is-a-carrot-for-mds-a-stick-for-pharma-companies.pdf?la=en )

> Download ( /-/media/files/publications/public/oncology-market-access-at-risk-is-a-carrot-for-mds-a-stick-for-pharma-companies.pdf?la=en )
Payers are providing doctors with financial incentives to comply with Oncology clinical pathways more aggressively than ever before. Pharma companies need stronger analytics to understand the impact these clinical pathway incentives will have on their brands.